Ciraparantag

Systematic (IUPAC) name
N,N'-(1,4-piperazinediyldi-3,1-propanediyl)bis[2-amino-5-[(aminoiminomethyl)amino]-, (2S,2'S)-pentanamide
Clinical data
Legal status
  • Investigational
Routes of
administration		 Intravenous
Pharmacokinetic data
Onset of action 10 min
Duration of action 24 hrs
Identifiers
CAS Number 1438492-26-2
ATC code None
PubChem CID 71576543
ChemSpider 33427375
UNII U2R67KV65Q
Synonyms PER977
Chemical data
Formula C22H48N12O2
Molar mass 512.71 g·mol−1

Ciraparantag (INN/USAN, or aripazine) is a drug under investigation as an antidote for a number of anticoagulant (anti–blood clotting) drugs, including factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), dabigatran, low molecular weight heparins and unfractionated heparin.[1][2]

Mechanism of action

According to in vitro studies, the substance binds directly to anticoagulants via hydrogen bonds from or to various parts of the molecule:[1]

Hydrogen bonds Rivaroxaban Apixaban Edoxaban Dabigatran Heparins
Guanidine part Green tick Green tick Green tick Green tick
α-Amino group Green tick Green tick Green tick Green tick
Amide nitrogen Green tick Green tick Green tick
Amide oxygen Green tick Green tick

Chemical properties

Ciraparantag consists of two L-arginine units connected with a piperazine containing linker chain.[1]

See also

Other anticoagulant antidotes

References

  1. 1 2 3 Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel Herbst 2015 (German)
  2. ↑ Ansell, J. E. (2015). "Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants". Journal of Thrombosis and Thrombolysis. doi:10.1007/s11239-015-1288-1. PMID 26449414.


This article is issued from Wikipedia - version of the Tuesday, November 10, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.